阿奇霉素结合普米克令舒雾化吸入治疗小儿肺炎支原体感染的疗效及对免疫功能的影响评价

Efficacy of Azithromycin Combined with Pulmicort Respules in the Treatment of Children with Mycoplasma Pneumoniae Infection and Its Effect on Immune Function

目的探讨并研究阿奇霉素结合普米克令舒雾化吸入治疗小儿肺炎支原体感染的临床效果以及对免疫功能的影响效果。方法方便选取该院小儿肺炎支原体感染患儿90例,选取时间为2015年7月—2018年8月,随机分成对照组和观察组,各45例,对照组采取阿奇霉素治疗,观察组采取阿奇霉素结合普米克令舒雾化吸入治疗,比较两组患儿的免疫功能情况和症状消失时间。结果观察组患儿的发热消失时间为(8.11±2.14)d,咳嗽消失时间为(6.21±2.17)d,咯痰消失时间为(3.11±0.31)d,胸闷消失时间为(3.13±0.15)d,喘息消失时间为(3.01±2.01)d,肺部啰音消失时间为(5.02±1.18)d;对照组患儿的发热消失时间为(10.62±2.41)d,咳嗽消失时间为(8.69±1.24)d,咯痰消失时间为(4.19±0.29)d,胸闷消失时间为(4.69±0.22),喘息消失时间为(4.65±2.21),肺部啰音消失时间为(6.95±1.42)d;差异有统计学意义(t=5.22、6.66、17.07、39.30、3.68、7.01,P<0.05)。观察组患儿的IgA水平为(1.98±0.11)g/L,IgG水平为(54.65±4.36)g/L,IgM水平为(1.69±0.41)g/L,IL-6水平为(14.15±10.21)ng/L,CD4+水平为(47.69±6.31)%,CD8+水平为(22.16±4.08)%;对照组患儿的IgA水平为(1.24±0.32)g/L,IgG水平为(32.19±6.28)g/L,IgM水平为(1.15±0.34)g/L,IL-6水平为(19.68±10.22)ng/L,CD4+水平为(44.19±5.19)%,CD8+水平为(27.95±4.36)%;差异有统计学意义(t=14.67、19.71、6.80、2.57、2.87、6.50,P<0.05)。结论采用阿奇霉素结合普米克令舒雾化吸入治疗小儿肺炎支原体感染,有效促进患儿的恢复,缩短临床症状恢复时间,改善患者的免疫功能。

Objective To investigate and study the clinical effect of azithromycin combined with Pulmicort Respules in the treatment of children with Mycoplasma pneumoniae infection and its effect on immune function.Methods 90 children with Mycoplasma pneumoniae infection in the hospital were convenienty selected.The patients were randomLy divided into the control group and the observation group from July 2015 to August 2018.The control group was treated with azithromycin.The observation group was treated with azithromycin pulmicort inhalation treatment,comparing the immune function of the two groups of children and the disappearance of symptoms.Results The disappearance time of fever in the observation group was(8.11±2.14)d,the disappearance time of cough was(6.21±2.17)d,the disappearance time of sputum sputum was(3.11±0.31)d,the disappearance time of chest tightness was(3.13±0.15)d,and wheezing disappearance time was(3.01±2.01)d,the disappearance time of lung arpeggios was(5.02±1.18)d;the time of fever disappearance in the control group was(10.62±2.41)d,and the time of disappearance of cough was(8.69±1.24)d,phlegm disappearance time(4.19±0.29)d,the time of chest tightness disappeared was(4.69±0.22)d,the time of disappearance of wheezing was(4.65±2.21)d,the time of disappearance of lung sound was(6.95±1.42)d,the difference was statistically significant(t=5.22,6.66,17.07,39.30,3.68,7.01,P<0.05).The IgA level of the observation group was(1.98±0.11)g/L,the IgG level was(54.65±4.36)g/L,the IgM level was(1.69±0.41)g/L,the IL-6 level was(14.15±10.21)ng/L,and the CD4+level was(47.69±6.31)%.The level of CD8+was(22.16±4.08)%;the IgA level of the control group was(1.24±0.32)g/L,the IgG level was(32.19±6.28)g/L,the IgM level was(1.15±0.34)g/L,and the IL-6 level was(19.68±10.22)ng/L,CD4+level was(44.19±5.19)%,CD8+level was(27.95±4.36)%,the difference was statistically significant(t=14.67,19.71,6.80,2.57,2.87,6.50,P<0.05).Conclusion Azithromycin combined with Pulmicort Respules inhalation in the treatment of children with Mycoplasma pneumoniae infection,effectively promote the recovery of children,shorten the recovery time of clinical symptoms and improve the immune function of patients.